GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (FRA:4QK) » Definitions » Change In Payables And Accrued Expense

Codexis (FRA:4QK) Change In Payables And Accrued Expense : €1.36 Mil (TTM As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Codexis Change In Payables And Accrued Expense?

Codexis's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2025 was €1.91 Mil. It means Codexis's Accounts Payable & Accrued Expense increased by €1.91 Mil from Dec. 2024 to Mar. 2025 .

Codexis's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was €-2.45 Mil. It means Codexis's Accounts Payable & Accrued Expense declined by €2.45 Mil from Dec. 2023 to Dec. 2024 .


Codexis Change In Payables And Accrued Expense Historical Data

The historical data trend for Codexis's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codexis Change In Payables And Accrued Expense Chart

Codexis Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.24 0.20 2.10 -2.45

Codexis Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.88 -0.22 0.84 -1.17 1.91

Codexis Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Codexis Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Codexis's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Codexis Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codexis Inc (FRA:4QK) » Definitions » Change In Payables And Accrued Expense
Traded in Other Exchanges
Address
200 Penobscot Drive, Redwood City, CA, USA, 94063
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Codexis Headlines

No Headlines